蛋白S抗体作为血友病B的辅助治疗
研究探讨抑制蛋白S(PS)能否延长凝血因子IX(FIX)的功能半衰期并增强血友病B(HB)疗效。体外实验显示PS抗体加速凝血并显著提高凝血酶峰值,在重型HB患者血浆中亦如此;HB小鼠联合注射PS抗体与FIX后,血栓诱导部位纤维蛋白蓄积较单用FIX高4.5倍。作者认为PS抗体可能成为提高儿童HB患者FIX替代治疗效果的辅助手段。
要点
- PS抗体在商业血浆和儿童HB患者血浆中加速凝血并显著提高凝血酶峰值
- HB小鼠联合PS抗体与FIX后纤维蛋白蓄积较单用FIX高4.5倍
- 作者认为PS抗体可能作为辅助手段提高儿童轻、中、重型HB的FIX替代疗效
核心结论
- 研究结果提示PS抗体可能作为有价值的辅助手段,提高儿童轻、中、重型HB患者FIX替代治疗的效果。
研究设计与样本
- 体外采用凝血时间和凝血酶生成实验,检测PS抗体在商业血浆及11例无其他合并症和凝血病的儿童HB患者血浆中增强FIX活性的效果。
- 体内在HB小鼠中评估存在FIXa±PS抗体时的血栓形成。
主要发现
- 在PS抗体存在下凝血速率加快。
- 在PS抗体存在下形成的凝血酶峰值显著更高,即使在重型HB患者血浆中亦如此。
- 注射PS抗体和FIX的HB小鼠,血栓诱导部位纤维蛋白蓄积较单用FIX的小鼠高4.5倍。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Hemophilia B (HB) is caused by an inherited deficiency of plasma coagulation factor IX (FIX). Approximately 60% of pediatric patients with HB possess a severe form of FIX deficiency (<1% FIX activity). Treatment typically requires replacement therapy through the administration of FIX. However, exogenous FIX has a limited functional half-life, and the natural anticoagulant protein S (PS) inhibits activated FIX (FIXa). PS ultimately limits thrombin formation, which limits plasma coagulation. This regulation of FIXa activity by PS led us to test whether inhibiting PS would extend the functional half-life of FIX and thereby prolong FIX-based HB therapy. We assayed clotting times and thrombin generation to measure the efficacy of a PS antibody for increasing FIX activity in commercially obtained plasma and plasma from pediatric patients with HB. We included 11 pediatric patients who lacked additional comorbidities and coagulopathies. In vivo, we assessed thrombus formation in HB mice in the presence of the FIXa ± PS antibody. We found an accelerated rate of clotting in the presence of PS antibody. Similarly, the peak thrombin formed was significantly greater in the presence of the PS antibody, even in plasma from patients with severe HB. Furthermore, HB mice injected with PS antibody and FIX had a 4.5-fold higher accumulation of fibrin at the thrombus induction site compared with mice injected with FIX alone. Our findings imply that a PS antibody would be a valuable adjunct to increase the effectiveness of FIX replacement therapy in pediatric patients who have mild, moderate, and severe HB.
引用
- Wilson HP, Pierre A, Paysse AL, et al. Protein S antibody as an adjunct therapy for hemophilia B. Blood Adv. 2024. PMID: 37773781. doi:10.1182/bloodadvances.2023010819
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。